TG Therapeutics (TGTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 11, 2026, and will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders will vote on electing six directors, ratifying KPMG LLP as auditor, approving executive compensation, and other business.

• Proxy materials are available online, with options for paper copies upon request; voting can be done online, by phone, or by mail.

Voting matters and shareholder proposals

• Proposals include electing six directors for a one-year term, ratifying KPMG LLP as auditor for 2026, and an advisory vote on executive compensation.

• Only shareholders of record as of April 14, 2026, are entitled to vote.

• Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of six members, with a mix of executive and independent directors; independence is reviewed annually.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• The board conducts annual self-evaluations and emphasizes diversity, skills, and experience in director selection.

• Directors are expected to attend all meetings; all attended the 2025 annual meeting.